ArticleBiochemistry research international2026
Modulatory Role of Arbutin on Hepatic Inflammation and Apoptosis After Mild Repetitive Traumatic Brain Injury in Experimental Rats: Involvement of NGF/TrkA and IL-6/JAK2/STAT3 Immune Signaling Crosstalk.
Article in Biochemistry research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Repetitive traumatic brain injury (RTBI) can cause long-term complications, including persistent neuroinflammation, which can extend beyond the central nervous system, impacting various peripheral organs as liver. This study aimed to explore the neuroprotective and hepatoprotective effects of arbutin treatment in a rat model of mild RTBI (mRTBI), focusing on nerve growth factor (NGF)/tropomyosin receptor kinase A (TrkA) signaling pathway along with the crosstalk between brain injury and hepatic dysfunction. Animals were randomly assigned into three groups: one served as a normal control (NC) group, while the other two groups were exposed to one blow for 5 days and either left for one week after the fifth blow (mRTBI) or received arbutin intraperitoneally (100 mg/kg/day for 7 days, mRTBI + ARB). Biochemical and histopathological changes were monitored in the brain cortex and the liver. This study revealed that arbutin treatment offered neuroprotection and preserved most of the neuronal structures. Arbutin demonstrated a significant increase in the cortical NGF and TrkA contents, along with a marked upregulation in cortical phosphoinositol-3 kinase (PI3K) and protein kinase B (AKt) mRNA levels compared to the mRTBI group. Furthermore, arbutin decreased cortical and serum inflammatory markers, reflecting its anti-inflammatory power. Peripherally, arbutin treatment resulted in a substantial decrease in hepatic inflammatory markers, Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) and caspase-3. These effects preserved hepatocellular histoarchitecture and reduced liver injury markers. Collectively, arbutin effectively modulated the NGF/TrkA signaling pathway, diminished inflammation, and alleviated the detrimental effects of mRTBI on both the brain and liver.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.